Metapyrin (Metamizole Sodium)

Metamizole works primarily by inhibiting cyclooxygenase enzymes, which reduces the synthesis of prostaglandins—chemical mediators that cause pain and fever. This inhibition leads to decreased inflammation signals, providing analgesic and antipyretic effects, although the full mechanism is not completely understood.

The appropriate dose of Metapyrin is determined by the prescribing clinician based on the patient’s condition, severity of symptoms, and individual health factors. Dosage regimens vary, and the prescriber will tailor the amount and frequency to achieve optimal pain relief or fever control.

Safety of metamizole during pregnancy and lactation has not been definitively established. Healthcare providers should evaluate the potential benefits against possible risks before prescribing Metapyrin to pregnant or nursing mothers, and alternative therapies may be considered when appropriate.

To order Metapyrin, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, and will request verification of trade or institutional credentials before providing pricing, availability, shipping details, and any necessary import documentation.

Metapyrin (metamizole) differs from traditional NSAIDs by having a distinct pyrazolone structure and a lower incidence of gastrointestinal irritation. However, it carries a unique risk of blood dyscrasias such as agranulocytosis, which is less common with many other analgesics. Clinicians weigh these factors when selecting an appropriate pain management option.

Metapyrin should be stored at room temperature, below 25 °C, in its original packaging to protect it from moisture and light. Keep the product out of reach of children and avoid storing it in humid environments such as bathrooms.

Metapyrin is administered orally, typically as a tablet or oral solution, depending on the marketed form. It should be taken with or without food as directed by the prescriber, and patients should follow the dosing schedule provided on the prescription label.

The most serious risks include agranulocytosis, a potentially life‑threatening drop in white blood cells, and severe allergic reactions such as anaphylaxis or Stevens‑Johnson syndrome. Prompt medical attention is required if signs of infection, rash, or breathing difficulty develop during therapy.

Metapyrin should be avoided in individuals with known hypersensitivity to metamizole or other pyrazolones, patients with a history of agranulocytosis, and those currently receiving other myelotoxic agents. Caution is also advised for patients with severe liver or kidney impairment.